Top Markets
#1 Siren Siren +45.54%
#2 Wrapped NXM Wrapped NXM +12.31%
#3 Cryptopia Cryptopia +9.12%
#4 Verus Coin Verus Coin +6.67%
#5 Mubarak Mubarak +6.18%
#6 Axelar Axelar +6.16%
#7 Notcoin Notcoin +5.51%
#8 OpenEden OpenEden +5.36%
#9 Stargate Finance Stargate Finance +4.89%
#10 Across Protocol Across Protocol +4.80%
Coin of the day
Siren Siren
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Silence Therapeutics plc Silence Therapeutics plc

Silence Therapeutics plc

SLN
Peringkat dalam Saham #12014
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Harga Saham
$13.34
Terakhir disinkronkan: 2026-08-28
Kapitalisasi Pasar
$629.93M
Perubahan (1 hari)
-0.84%
Perubahan (1 tahun)
177.26%
Negara
GB
Perdagangan Silence Therapeutics plc (SLN)

Kategori

Healthcare
Riwayat harga saham Silence Therapeutics plc (SLN)
Harga penutupan tertinggi: $13.70 pada 2026-08-01

Harga penutupan terendah: $18.26 pada 2020-09-01
Riwayat harga saham Silence Therapeutics plc dari 2020 hingga 2026
Performa harga saham tahunan
Tahun Performa
2026 (TTM) 10.68%
2025 -10.61%
2024 -54.38%
2023 3.22%
2022 -37.25%
2021 25.25%
2020 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.20 -12.94%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH